Cytokinetics (CYTK) Stock Price, Quote, News & History | Benzinga

Cytokinetics Inc (CYTK) Stock Price, Quote, News & History

CYTKNASDAQ

Trade with Public

Trade with Public

$77.46

0.370.48%

At close: Aug 24, 5:00 PM EST

$77.60

0.510.66%

Pre-Market: 7:30 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$77.46

Volume / Avg.

501.00 / 2.00M

Day Range

- - -

52 Wk Range

35.22 - 88.31

Market Cap

$10.79B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

49

Short Interest

16.8%

Days to Cover

9.63

Recent Cytokinetics, Incorporated News

New AI ETF Bets on Healthcare's $9 Trillion Opportunity

Tema's new Healthcare AI ETF (HLTH), targets AI-powered drug discovery, diagnostics, robotics and patient care.

Chandrima Sanyal

Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Higher On Tuesday

Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidance. Other big gainers include EverQuote, Sterling Infrastructure, and DigitalOcean.

Avi Kapoor

Cytokinetics Stock Rallies After Pivotal Heart Disease Study Hits Dual Primary Endpoints

Cytokinetics stock jumps after Phase 3 ACACIA-HCM trial meets endpoints, showing improved exercise performance and heart function metrics.

Vandana Singh

The Year-End 2025 Biotech Rally And What It Means For 2026

Hillary Remy

Why Is Edgewise Therapeutics Stock Soaring Wednesday?

Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for hypertrophic cardiomyopathy.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-555.45M

Investing Cash Flow (TTM)

-503.68M

Financing Cash Flow (TTM)

1.24B

Free Cash Flow (TTM)

-580.72M

Capital Expenditure (TTM)

-25.26M

Net Change in Cash (TTM)

182.67M

Analyst Trends and Forecast

8

May

3

Jun

1

Jul

5

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$10.87B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

142.47

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-9.32%

Earnings Yield % (FWD)

-7.96%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$1.25

Company Debt

Total Debt

$1.15B

LT Debt

$1.12B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$414.26M

Total Cash

$255.27M

Debt to Equity

-

Issuance of Debt (TTM)

$315.20M

Repayment of Debt (TTM)

-$414.26M

Key Statistics

Open

-

Close

$77.46

Volume / Avg.

501.00 / 2.00M

Day Range

- - -

52 Wk Range

35.22 - 88.31

Market Cap

$10.79B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

49

Short Interest

16.8%

Days to Cover

9.63

About

Sector

Health Care

Industry

Biotechnology

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Cytokinetics (CYTK) stock?

A

You can purchase shares of Cytokinetics (NASDAQ:CYTK) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Cytokinetics (CYTK) competitors?

A

Other companies in Cytokinetics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Cytokinetics (CYTK) stock?

A

Cytokinetics has a consensus price target of $99.13.

Q

What is the current price for Cytokinetics (CYTK)?

A

The stock price for Cytokinetics (NASDAQ: CYTK) is $77.6 last updated August 26, 2026 at 7:29 AM EDT.

Q

Does Cytokinetics (CYTK) pay a dividend?

A

There are no upcoming dividends for Cytokinetics.

Q

When is Cytokinetics (NASDAQ:CYTK) reporting earnings?

A

Cytokinetics does not have any upcoming earnings scheduled.

Q

Is Cytokinetics (CYTK) going to split?

A

There is no upcoming split for Cytokinetics.

Q

What sector and industry does Cytokinetics (CYTK) operate in?

A

Cytokinetics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.